text stringlengths 1 5.46k |
|---|
10.5 Public Announcements. .........................................................................................50 |
10.6 Publications. ...........................................................................................................50 |
10.7 Return of Confidential Information. ......................................................................50 |
10.8 Survival. .................................................................................................................51 |
ARTICLE 11 REPRESENTATIONS AND WARRANTIES .................................................51 |
11.1 Representations and Warranties of Both Parties. ...................................................51 |
11.2 Representations, Warranties and Covenants, as applicable, of AbCellera. ...........51 |
11.3 Representations, Warranties and Covenants, as applicable, of AbbVie. ...............57 |
11.4 Additional Covenants of AbCellera. ......................................................................57 |
11.5 Disclaimer. .............................................................................................................58 |
11.6 Anti-Bribery and Anti-Corruption Compliance.. ...................................................58 |
11.7 Bring Down Limitations. .......................................................................................58 |
ARTICLE 12 INDEMNIFICATION; INSURANCE ..............................................................59 |
12.1 Indemnification by AbbVie. ..................................................................................59 |
12.2 Indemnification by AbCellera. ...............................................................................59 |
12.3 Procedure. ..............................................................................................................60 |
12.4 Insurance. ...............................................................................................................62 |
12.5 Limitation of Liability. ...........................................................................................62 |
ARTICLE 13 TERM AND TERMINATION .........................................................................63 |
13.1 Term. ......................................................................................................................63 |
13.2 Termination. ...........................................................................................................63 |
13.3 Modification in Lieu of Termination. ....................................................................64 |
13.4 Effects of Termination of Agreement. ...................................................................65 |
13.5 Reverse Royalty. ....................................................................................................67 |
13.6 Accrued Rights; Surviving Provisions of the Agreement. .....................................67 |
ARTICLE 14 MISCELLANEOUS .........................................................................................68 |
14.1 Governing Law; Service. .......................................................................................68 |
14.2 Dispute Resolution. ................................................................................................68 |
14.3 Assignment. ...........................................................................................................69 |
14.4 Force Majeure. .......................................................................................................71 |
14.5 Notices. ..................................................................................................................71 |
14.6 Export Clause. ........................................................................................................72 |
14.7 Waiver; Non-Exclusion of Remedies. ...................................................................72 |
14.8 Further Assurance. .................................................................................................72 |
14.9 Severability. ...........................................................................................................73 |
14.10 Equitable Relief. ....................................................................................................73 |
14.11 Applicability of 11 U.S.C. § 365(n). ......................................................................74 |
14.12 Entire Agreement; Amendments. ...........................................................................74 |
14.13 Relationship of the Parties. ....................................................................................74 |
14.14 Headings; Construction; Interpretation. .................................................................74 |
14.15 Books and Records. ...............................................................................................75 |
14.16 English Language...................................................................................................75 |
14.17 Parties in Interest....................................................................................................75 |
14.18 Counterparts. ..........................................................................................................75 |
EXHIBITS AND SCHEDULES |
EXHIBITS |
Exhibit A Research Plans |
SCHEDULES |
Schedule 1.7 Existing AbCellera Background Patents |
Schedule 6.2.2 Approved Third Party Contractors |
Schedule 11.2 AbCellera Disclosure Schedule |
Schedule 11.2.7 Existing In-License Agreements |
Schedule 14.2.2 ADR Procedures |
COLLABORATION AND OPTION AGREEMENT |
This COLLABORATION AND OPTION AGREEMENT (this "Agreement") is entered into and made effective as of December 14, 2022 (the "Effective Date"), by and between AbCellera Biologics Inc., a corporation organized under the laws of British Columbia, Canada, having a place of business at 2215 Yukon Street, Vancouver, BC V5Y 0A... |
RECITALS |
WHEREAS, AbCellera has developed a proprietary platform technology for therapeutic antibody (and bi-specific antibody) discovery; |
WHEREAS, AbbVie possesses expertise in the research, development, manufacturing and commercialization of human pharmaceuticals; and |
WHEREAS, AbCellera and AbbVie desire to engage in a collaborative effort pursuant to which AbCellera will carry out certain preclinical research activities set forth in each Research Plan (as defined below) and pursuant to which AbbVie will have an option to purchase, develop and commercialize Earn-Out Products (as def... |
NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: |
ARTICLE 1 DEFINITIONS |
As used in this Agreement, the following terms will have the meanings set forth in this Article 1 (Definitions) unless context dictates otherwise: |
1.1 "AbbVie" has the meaning set forth in the introductory paragraph. |
1.2 "AbbVie Background Know-How" means all information (including regulatory data, files, approvals and other documentation) and Know-How, other than Research Know-How, that is (a) Controlled by AbbVie or any of its Affiliates as of the Effective Date or at any time during the Term, (b) is not generally known and (c) i... |
1.3 "AbbVie Supplies" has the meaning set forth in Section 2.5.5 (AbbVie Materials). |
1.4 "AbCellera" has the meaning set forth in the introductory paragraph. |
1.5 "AbCellera Background IP" means the AbCellera Background Know-How and AbCellera Background Patents, in each case, excluding any AbCellera Improvements. |
1.6 "AbCellera Background Know-How" means all information (including regulatory data, files, approvals and other documentation) and Know-How (including any such information and Know-How that relates to the AbCellera Platform Technology), other than Research Know-How, that is (a) Controlled by AbCellera or any of its Af... |
1.7 "AbCellera Background Patents" means all Patent Rights, other than Research Patents, that (a) are Controlled by AbCellera or any of its Affiliates as of the Effective Date or at any time during the Term and (b) (i) are necessary or useful for the conduct of activities allocated to either Party under any Research Pl... |
1.8 "AbCellera Improvement Patents" has the meaning set forth in Section 1.9 (AbCellera Improvements). |
1.9 "AbCellera Improvements" means (a) all Research Know-How that (i) constitutes an improvement to the AbCellera Background IP (including any improvement to the AbCellera Platform Technology), (ii) is conceived, reduced to practice, generated, discovered, developed or otherwise made solely by or on behalf of AbCellera... |
1.10 "AbCellera Partner Agreement" means any Contract by and between AbCellera or any of its Affiliates and any Third Party effective prior to the Nomination Date of a Nominated Target, as such Contract exists on the Nomination Date, pursuant to which AbCellera or such Affiliate has granted such Third Party the right t... |
1.11 "AbCellera Platform Technology" means (a) AbCellera's proprietary platform technology (including the OrthoMab Platform Technology) to identify and characterize new Antibodies, which combines (i) immunizations, isolation and enrichment of immune cells, microfluidics, microfabricated device formats, designs, and ass... |
1.12 "Accounting Standards" means, with respect to a Party or its Affiliates or its or their (sub)licensees/Licensees/Sublicensees, United States generally accepted accounting principles or International Financial Reporting Standards as issued by the International Accounting Standards Board, as applicable, in each case... |
1.13 "Achieved Milestone Event" has the meaning set forth in Section 7.5 (Development and Regulatory Milestone Payments). |
1.14 "Acquired Assets" means, collectively, (i) the Collaboration Program Assets, and (ii) the Option Program Assets on and after the applicable Acquisition Option Effective Date. |
1.15 "Acquisition Option" has the meaning set forth in Section 2.7.1 (Grant of Acquisition Option). |
1.16 "Acquisition Option Effective Date" means, with respect to each Option Program, the date upon which AbbVie delivers to AbCellera an Exercise Notice with respect to such Option Program in accordance with Section 14.5 (Notices); provided that, if AbbVie determines in its sole discretion prior to the delivery of any ... |
1.17 "Acquisition Option Exercise Fee" has the meaning set forth in Section 7.4 (Acquisition Option Exercise Fee). |
1.18 "Acquisition Option Period" means, with respect to the Initial Option Program, the time period commencing on the Effective Date (or, with respect to any Additional Option Program, the Addition Confirmation Date) and, subject to extension pursuant to Section 2.5.2(d) (Diligence; Data Package; Information Requests) ... |
1.19 "Acquisition Option Period Activities" has the meaning set forth in Section 2.7.1 (Grant of Acquisition Option). |
1.20 "Addition Confirmation Date" has the meaning set forth in Section 2.2.3 (Additional Option Programs). |
1.21 "Additional Option Program" has the meaning set forth in Section 2.2.3 (Additional Option Programs). |
1.22 "Additional Option Program Fee" has the meaning set forth in Section 7.2 (Additional Option Program Fee). |
1.23 "Additional Option Program Notice" has the meaning set forth in Section 2.2.3 (Additional Option Programs). |
1.24 "ADR" has the meaning set forth in Section 14.2.1 (General). |
1.25 "Adverse Ruling" has the meaning set forth in Section 13.2.1(a) (Material Breach). |
1.26 "Affiliate" means, with respect to a Person, any Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such first Person for so long as such Person controls, is controlled by or is under common control with such first Person, regardless o... |
1.27 "Agreement" has the meaning set forth in the introductory paragraph. |
1.28 "Alliance Manager" has the meaning set forth in Section 3.7 (Alliance Managers). |
1.29 "Alloy" has the meaning set forth in Section 2.5.4 (Alloy Mouse). |
1.30 "Alloy Mouse" has the meaning set forth in Section 2.5.4 (Alloy Mouse). |
1.31 "Alloy Mouse Antibody" means an Earn-Out Antibody that is derived from an Alloy Mouse as permitted in the applicable Research Plan. |
1.32 "Alloy Mouse Product" means a product that comprises or contains (a) an Alloy Mouse Antibody or (b) a Derived Antibody of an Alloy Mouse Antibody. |
1.33 "Alloy Mouse Records" has the meaning set forth in Section 5.3.1(a) (Record-Keeping; Audit). |
1.34 "Alloy Selection Notice" has the meaning set forth in Section 5.3 (Alloy Selection Notice; Updated Alloy Selection Notice). |
1.35 "Amount" has the meaning set forth in Section 7.17.2 (Withholding Taxes). |
1.36 "Animal Health" means diagnostic, prophylactic and therapeutic uses for animals. |
1.37 "Annual Net Sales" means, with respect to an Earn-Out Product, the total Net Sales of such Earn-Out Product in the Territory in a particular Calendar Year. |
1.38 "Annual Net Sales Milestone Threshold" has the meaning set forth in Section 7.7 (Sales-Based Milestone Payments). |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.